+709.2%
ONDS vs MRNA
+27.9%
+681.2%
-75.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.5% | +0.7% | -1.3% | -0.6% |
| 7D | -5.0% | -8.2% | +3.2% | -4.4% |
| 30D | -25.6% | +125.6% | -151.1% | -34.6% |
| 3M | -22.1% | +197.1% | -219.2% | -37.3% |
| 6M | -27.6% | +148.5% | -176.1% | -39.0% |
| YTD | -25.7% | +363.3% | -389.0% | -48.1% |
| 1Y | +30.4% | +462.0% | -431.6% | -14.5% |
| All | +709.2% | +27.9% | +681.2% | +451.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling